Multi-line Resistant Diffuse Large B-cell Lymphoma (DLBCL)

Mr. X, a male patient, presented with multi-line resistant diffuse large B-cell lymphoma (DLBCL), a challenging condition characterized by the resistance of the tumor to multiple lines of treatment. Upon initial evaluation, Mr. X complained of significant abdominal pain, prompting further investigation.

Imaging studies, including Figure 1, revealed a large mass in the abdominal cavity, indicative of extensive disease involvement. The presence of such a mass not only contributed to Mr. X's abdominal discomfort but also raised concerns about the progression and aggressiveness of his lymphoma.

Considering the limited success of previous treatment lines and the urgent need for effective intervention, Mr. X was enrolled in a clinical trial for CD19+22 CAR-T cell therapy. After undergoing the necessary preparatory steps, including pretreatment, Mr. X received the infusion of CD19+22 CAR-T cells.

Remarkably, Figure 2, taken three months after the return infusion of CD19+22 CAR-T cells, showed complete disappearance of the abdominal mass. This remarkable response to treatment indicated a successful outcome, with the lymphoma effectively eradicated.

Throughout his treatment journey, Mr. X received comprehensive care and support from the medical team. This included close monitoring of his condition, management of treatment-related side effects, and emotional support to help him cope with the challenges of battling cancer.

Additionally, beyond medical care, we provided Mr. X with a range of services to ensure his overall well-being during his treatment. This included arranging comfortable accommodation for him, providing nutritious meals tailored to his dietary needs, organizing transportation for his appointments and travel requirements, and offering psychological support for him and his family to help them navigate through this challenging period.

Mr. X's case highlights the potential of innovative therapies like CAR-T cell therapy in overcoming multi-line resistant DLBCL. It underscores the importance of continued research and development in the field of oncology to provide hope and effective treatment options for patients facing difficult-to-treat cancers like DLBCL.

Before & 3 months after infusion